Johnson & Johnson (NYSE: JNJ) announced Friday the start of a safety and immunogenicity clinical trial in Sierra Leone of a preventive Ebola vaccine regimen in development at its Janssen Pharmaceutical Companies.
Trial recruitment is underway, and the first volunteers have received their initial vaccine dose. This is stated to be the first study conducted of Janssen’s Ebola prime-boost vaccine regimen in a West African country affected by the recent Ebola epidemic.
The new study, EBOVAC-Salone, will take place in Sierra Leone’s Kambia district, where some of the country’s most recent Ebola cases have been reported.
The regimen being tested uses a combination of two vaccine components based on AdVac technology from Crucell Holland B.V., one of the Janssen Pharmaceutical Companies, and MVA-BN technology from Bavarian Nordic.
Volunteers in the study will first be given the AdVac dose to prime their immune system, and then the MVA-BN dose two months later to boost their immune response, with the goal of potentially strengthening and optimizing the duration of the immunity.
Support Independent Fearless Journalism
In today's media world controlled by corporates and politicians, it is extremely difficult for independent editorial voices to survive. RMN News Service has been maintaining editorial freedom and offering objective content for the past 10 years despite enormous pressures and extreme threats.
In order to serve you fearlessly in this cut-throat world, RMN News Service urges you to support us financially with your donations. You can choose the amount that you want to donate from the options given below.
You also can select any of the Payment Methods:
Offline Donation: To know our bank details for online bank transfer and payment by cheque in Indian rupees.
PayPal: To make payment by Credit / Debit Card or PayPal account.